联合检测血清SCC、CEA、CA125、CA199在宫颈癌诊断中的价值被引量：22

导出

摘要目的探讨血清肿瘤标志物鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)、糖链抗原125(CA125)、糖链抗原199(CA199)在宫颈癌诊断中临床应用价值。方法收集病理确诊的92例宫颈癌患者作为宫颈癌组,另选体检中心同期健康体检者80例为对照组,检测血清SCC、CEA、CA125、CA199浓度,并分析其与病理类型、临床分期的相关性。结果宫颈癌组患者血清SCC、CEA、CA125、CA199水平明显高于对照组,宫颈鳞癌组SCC的阳性率明显高于宫颈腺癌组,CEA、CA125、CA199阳性率明显低于宫颈腺癌组,临床Ⅲ/Ⅳ期宫颈癌患者肿瘤标志物阳性率明显高于Ⅰ/Ⅱ期,联合检测的敏感性显著高于单独检测,差异均有统计学意义(P<0.05)。结论 SCC-Ag、CEA、CA125、CA199联合检测可有效提高宫颈癌诊断的敏感性,对鉴别病理类型及临床分期具有一定的意义,值得临床推广应用。

作者罗业琳雷嘉黄卓华

机构地区广西壮族自治区梧州市红十字会医院妇科

出处《临床合理用药杂志》 2016年第13期137-138,共2页 Chinese Journal of Clinical Rational Drug Use

关键词肿瘤标志物 SCC CEA CA125 CA199 宫颈癌

分类号 R737.33 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1朱茜,刘岿然,邓新.血清鳞状细胞癌抗原和癌胚抗原及癌抗原125联合检测在宫颈癌诊断中的临床意义[J].中国综合临床,2013,29(6):646-648. 被引量：24
2雷君,张彤,谌宏鸣.5种肿瘤标志物在宫颈癌检测中的信息提示和临床应用[J].新疆医科大学学报,2005,28(2):165-167. 被引量：14
3刘馨,白艳香.血清肿瘤标志物和宫颈癌分期的相关性及其机制[J].中国老年学杂志,2014,34(11):2945-2946. 被引量：10
4Jeong BK,Choi DH,Huh SJ,et al.The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix. Radiat Oncol J . 2011
5I. OGINO,H. NAKAYAMA,N. OKAMOTO,T. KITAMURA,T. INOUE.??The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy(J)International Journal of Gynecological Cancer . 2006 (3)
6Angiolo Gadducci,Roberta Tana,Stefania Cosio,Andrea Riccardo Genazzani.??The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature(J)Critical Reviews in Oncology and Hematology . 2007 (1)

二级参考文献23

1万文徽,李吉友.肿瘤标志的临床应用[J].中华医学检验杂志,1997,20(1):49-51. 被引量：180
2蒋一宁.肿瘤核医学[M].北京:人民卫生出版社,2002.98-101.
3de Bruijn HW, Duk JM, van der Zee AG, et al. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix[J]. Tumour Biol, 1998,19 (6) : 505-516.
4Borras G, Molina R, Xercavins J, et al. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix[J]. Gynecol Oncol, 1995,57(2), 205-211.
5Suzuki Y, Nakano T, Ohno T, et al. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy[J]. J Cancer Res Clin Oncol, 2000 ,126(6):332-336.
6Parkin DM, Bray F, Feday J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin,2005,55(2) :74-108.
7Schiffman M, Castle PE, Jemnimo J, et al. Human papillomavirus and cervical cancer [J]. Lancet,2007,370(9590) :890-907.
8Molina R, Auge JM, Escudero JM, et al. Mucins CA 125, CA 19. 9, CA 15.3 and TAG-72. 3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE [ J]. Tumour Biol,2008,29(6) :371-380.
9Duffy MJ. Evidence for the clinical use of tumour markers [J]. Ann Clin Biochem,20Od- ,41 ( Pt 5 ) :370-377.
10Molina R,Filella X,Aug： JM,et al. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA [ J ]. Anticancer Res,2005,25(3A) :1765-1771.